Epigen is an incubator of life science projects focused on developing new product opportunities with strong IP to be advanced into clinical development. We operate through collaboration with academic groups in their respective areas of expertise. Epigen provides strategic project management and world-class medicinal chemistry support. The company founders have considerable successful experience in drug discovery and development and a track record of advancing compounds to the clinic and commercial registration. Epigen’s unique operating model provides access to a complete team of experts and resources while keeping low overhead expenses, thus allowing for the efficient development of assets and maximal creation of value. The company creates value by bridging the gap between lead identification and clinical proof-of concept. Ideally, each asset will have a 2-4 years turnaround time from IP to IND enablement and completion of Phase 1 studies. These would then be sold or partnered with Pharma companies.